Clinical Trials

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Do you or your child have dyslipidemia? This study is exploring how different diagnostic tests can help us understand how lipid disorders, including high blood cholesterol and high blood triglycerides, affect the body. Information from this study may help improve the way lipid disorders are diagnosed or treated in the future. Participants in this study must be at least 2 years old. The study is being conducted in Bethesda, Maryland.

Are you a black man or women who has obesity and lives in Washington D.C.? This study aims to understand the health and health needs of people in predominately black churches in Washington, D.C. This information will help researchers design programs to improve heart health in these communities. To participate in this study, you must be between 19 and 85 years old and attend one of the churches in the study. This study is based in Bethesda, Maryland.

Do you have overweight or obesity and are not in a weight management program? This study is investigating whether self-weighing, combined with follow-up encouragement, promotes weight loss and use of weight management resources. To participate in this study, you must be between 18 and 70 and overweight or obese and with weight-related comorbidity (hypertension, type II diabetes, pre-diabetes, dyslipidemia, sleep apnea). This study is located in Gainesville, Florida.